Aurinia Pharmaceuticals (AUPH) Rating Lowered to Sell at BidaskClub

Share on StockTwits

BidaskClub downgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a hold rating to a sell rating in a report published on Friday.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald set a $18.00 target price on Aurinia Pharmaceuticals and gave the company a buy rating in a research note on Monday, October 1st. HC Wainwright reiterated a buy rating and issued a $15.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, September 26th. ValuEngine upgraded Aurinia Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, August 28th. Finally, Zacks Investment Research downgraded Aurinia Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 24th. Two analysts have rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of Buy and an average target price of $11.95.

AUPH opened at $5.54 on Friday. The company has a market cap of $468.42 million, a price-to-earnings ratio of -6.02 and a beta of 2.22. Aurinia Pharmaceuticals has a 52 week low of $4.41 and a 52 week high of $6.69.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The firm had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.07 million. Aurinia Pharmaceuticals had a negative return on equity of 36.10% and a negative net margin of 7,280.85%. Equities analysts expect that Aurinia Pharmaceuticals will post -0.73 EPS for the current year.

Several hedge funds have recently made changes to their positions in the business. FMR LLC grew its stake in shares of Aurinia Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after purchasing an additional 95,650 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Aurinia Pharmaceuticals by 6.1% in the 3rd quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after purchasing an additional 105,300 shares during the last quarter. BlackRock Inc. grew its stake in shares of Aurinia Pharmaceuticals by 45.2% in the 1st quarter. BlackRock Inc. now owns 1,045,121 shares of the biotechnology company’s stock valued at $5,424,000 after purchasing an additional 325,408 shares during the last quarter. Ironwood Investment Management LLC grew its stake in shares of Aurinia Pharmaceuticals by 18.0% in the 2nd quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock valued at $1,231,000 after purchasing an additional 33,279 shares during the last quarter. Finally, Creative Planning grew its stake in shares of Aurinia Pharmaceuticals by 8.2% in the 2nd quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock valued at $964,000 after purchasing an additional 13,000 shares during the last quarter. Institutional investors own 25.27% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: How to Invest in the Dividend Aristocrat Index

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply